|
1
|
Islami F, Miller KD, Siegel RL, Fedewa SA,
Ward EM and Jemal A: Disparities in liver cancer occurrence in the
United States by race/ethnicity and state. CA Cancer J Clin.
67:2966–289. 2017. View Article : Google Scholar
|
|
2
|
Breathnach OS, Freidlin B, Conley B, Green
MR, Johnson DH, Gandara DR, O'Connell M, Shepherd FA and Johnson
BE: Twenty-two years of phase III trials for patients with advanced
non-small-cell lung cancer: Sobering results. J Clin Oncol.
19:1734–1742. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Reck M, Heigener DF, Mok T, Soria JC and
Rabe KF: Management of non-small-cell lung cancer: Recent
developments. Lancet. 382:709–719. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cufer T, Ovcaricek T and O'Brien ME:
Systemic therapy of advanced non-small cell lung cancer:
Major-developments of the last 5-years. Eur J Cancer. 49:1216–1225.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yasukawa M, Sawabata N, Kawaguchi T, Kawai
N, Nakai T, Ohbayashi C and Taniguchi S: Histological grade:
Analysis of prognosis of non-small cell lung cancer after complete
resection. In Vivo. 32:1505–1512. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang L, Shang X and Feng Q: LncRNA TATDN1
contributes to the cisplatin resistance of non-small cell lung
cancer through TATDN1/miR-451/TRIM66 axis. Cancer Biol Ther.
20:261–271. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Roach MC, Bradley JD and Robinson CG:
Optimizing radiation dose and fractionation for the definitive
treatment of locally advanced non-small cell lung cancer. J Thorac
Dis. 10 (Suppl 21):S2465–S2473. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chu T, Jiang L, Ying W and Han B: M30/M65
ratio predicts the outcome of paclitaxel chemotherapy for NSCLC.
Clin Transl Oncol. 19:326–331. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu YL, Saijo N, Thongprasert S, Yang JC,
Han B, Margono B, Chewaskulyong B, Sunpaweravong P, Ohe Y, Ichinose
Y, et al: Efficacy according to blind independent central review:
Post-hoc analyses from the phase III, randomized, multicenter,
IPASS study of first-line gefitinib versus carboplatin/paclitaxel
in Asian patients with EGFR mutation-positive advanced NSCLC. Lung
Cancer. 104:119–125. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lu Y, Wang J, Liu L, Yu L, Zhao N, Zhou X
and Lu X: Curcumin increases the sensitivity of
Paclitaxel-resistant NSCLC cells to Paclitaxel through
microRNA-30c-mediated MTA1 reduction. Tumour Biol.
doi:10.1177/1010428317698353.
|
|
11
|
Kubo N, Noda SE, Takahashi A, Yoshida Y,
Oike T, Murata K, Musha A, Suzuki Y, Ohno T, Takahashi T, et al:
Radiosensitizing effect of carboplatin and paclitaxel to carbon-ion
beam irradiation in the non-small-cell lung cancer cell line H460.
J Radiat Res (Tokyo). 56:229–238. 2015. View Article : Google Scholar
|
|
12
|
Ding J, Li M, Deng L and Li T: Study on
biological characteristics and mechanism of paclitaxel induced drug
resistance in endometrial carcinoma cells. BioMed Res Int.
2018:83720852018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sobue S, Mizutani N, Aoyama Y, Kawamoto Y,
Suzuki M, Nozawa Y, Ichihara M and Murate T: Mechanism of
paclitaxel resistance in a human prostate cancer cell line, PC3-PR,
and its sensitization by cabazitaxel. Biochem Biophys Res Commun.
479:808–813. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tsakonas G, De Petris L and Ekman S:
Management of brain metastasized non-small cell lung cancer (NSCLC)
- From local treatment to new systemic therapies. Cancer Treat Rev.
54:122–131. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang H, Liu Q, Kong L and Xu S: Mucin 1
downregulation impairs the anti-necroptotic effects of
glucocorticoids in human bronchial epithelial cells. Life Sci.
221:168–177. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Song ZB, Gao SS, Yi XN, Li YJ, Wang QM,
Zhuang ZH and Wang LD: Expression of MUC1 in esophageal
squamous-cell carcinoma and its relationship with prognosis of
patients from Linzhou city, a high incidence area of northern
China. World J Gastroenterol. 9:404–407. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sakamoto H, Yonezawa S, Utsunomiya T,
Tanaka S, Kim YS and Sato E: Mucin antigen expression in gastric
carcinomas of young and old adults. Hum Pathol. 28:1056–1065. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wreesmann VB, Sieczka EM, Socci ND, Hezel
M, Belbin TJ, Childs G, Patel SG, Patel KN, Tallini G, Prystowsky
M, et al: Genome-wide profiling of papillary thyroid cancer
identifies MUC1 as an independent prognostic marker. Cancer Res.
64:3780–3789. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Morari EC, Silva JR, Guilhen AC, Cunha LL,
Marcello MA, Soares FA, Vassallo J and Ward LS: Muc-1 expression
may help characterize thyroid nodules but does not predict
patients' outcome. Endocr Pathol. 21:242–249. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Abrosimov A, Saenko V, Meirmanov S,
Nakashima M, Rogounovitch T, Shkurko O, Lushnikov E, Mitsutake N,
Namba H and Yamashita S: The cytoplasmic expression of MUC1 in
papillary thyroid carcinoma of different histological variants and
its correlation with cyclin D1 overexpression. Endocr Pathol.
18:68–75. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nabavinia MS, Gholoobi A, Charbgoo F,
Nabavinia M, Ramezani M and Abnous K: Anti-MUC1 aptamer: A
potential opportunity for cancer treatment. Med Res Rev.
37:1518–1539. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun ZG, Zhang M, Yang F, Gao W, Wang Z and
Zhu LM: Clinical and prognostic significance of signal transducer
and activator of transcription 3 and mucin 1 in patients with
non-small cell lung cancer following surgery. Oncol Lett.
15:4278–4288. 2018.PubMed/NCBI
|
|
23
|
Xu T, Li D, Wang H, Zheng T, Wang G and
Xin Y: MUC1 downregulation inhibits non-small cell lung cancer
progression in human cell lines. Exp Ther Med. 14:4443–4447.
2017.PubMed/NCBI
|
|
24
|
Sun H, Zhou X, Bao Y, Xiong G, Cui Y and
Zhou H: Involvement of miR-4262 in paclitaxel resistance through
the regulation of PTEN in non-small cell lung cancer. Open Biol.
9:1802272019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bocci G, Di Paolo A and Danesi R: The
pharmacological bases of the antiangiogenic activity of paclitaxel.
Angiogenesis. 16:481–492. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Milane L, Duan Z and Amiji M: Development
of EGFR-targeted polymer blend nanocarriers for combination
paclitaxel/lonidamine delivery to treat multi-drug resistance in
human breast and ovarian tumor cells. Mol Pharm. 8:185–203. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang L, Liu X, Ren Y, Zhang J, Chen J,
Zhou W, Guo W, Wang X, Chen H, Li M, et al: Cisplatin-enriching
cancer stem cells confer multidrug resistance in non-small cell
lung cancer via enhancing TRIB1/HDAC activity. Cell Death Dis.
8:e27462017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lehnert M: Clinical multidrug resistance
in cancer: A multifactorial problem. Eur J Cancer. 32A:912–920.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gottesman MM and Pastan I: Biochemistry of
multidrug resistance mediated by the multidrug transporter. Annu
Rev Biochem. 62:385–427. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Volm M, Koomägi R, Efferth T and Mattern
J: Protein expression profiles of non-small cell lung carcinomas:
Correlation with histological subtype. Anticancer Res.
22:2321–2324. 2002.PubMed/NCBI
|
|
31
|
Wani MC, Taylor HL, Wall ME, Coggon P and
McPhail AT: Plant antitumor agents. VI. The isolation and structure
of taxol, a novel antileukemic and antitumor agent from Taxus
brevifolia. J Am Chem Soc. 93:2325–2327. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Waud WR, Gilbert KS, Harrison SD Jr and
Griswold DP Jr: Cross-resistance of drug-resistant murine P388
leukemias to taxol in vivo. Cancer Chemother Pharmacol. 31:255–257.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Morin PJ: Drug resistance and the
microenvironment: Nature and nurture. Drug Resist Updat. 6:169–172.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kufe DW: MUC1-C oncoprotein as a target in
breast cancer: Activation of signaling pathways and therapeutic
approaches. Oncogene. 32:1073–1081. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ren J, Agata N, Chen D, Li Y, Yu WH, Huang
L, Raina D, Chen W, Kharbanda S and Kufe D: Human MUC1
carcinoma-associated protein confers resistance to genotoxic
anticancer agents. Cancer Cell. 5:163–175. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Horn G, Gaziel A, Wreschner DH,
Smorodinsky NI and Ehrlich M: ERK and PI3K regulate different
aspects of the epithelial to mesenchymal transition of mammary
tumor cells induced by truncated MUC1. Exp Cell Res. 315:1490–1504.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wei X, Lai Y, Li J, Qin L, Xu Y, Zhao R,
Li B, Lin S, Wang S, Wu Q, et al: PSCA and MUC1 in non-small-cell
lung cancer as targets of chimeric antigen receptor T cells.
OncoImmunology. 6:e12847222017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bouillez A, Adeegbe D, Jin C, Hu X, Tagde
A, Alam M, Rajabi H, Wong KK and Kufe D: MUC1-C promotes the
suppressive immune microenvironment in non-small cell lung cancer.
OncoImmunology. 6:e13389982017. View Article : Google Scholar : PubMed/NCBI
|
